FRESCO–2 trial and fruquintinib: A clearer picture of the control arm by Sruthi Ranganathan, Alyson Haslam, Timothée Olivier, Vinay Prasad

Get full text

Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more by Vinay Prasad, Alyson Haslam, Timothée Olivier, Dagney Ochoa, Eduardo Fernandez

Get full text

Analysis of the Political Viewpoint of Policy Statements From Professional Medical Organizations Using ChatGPT With GPT-4: Cross-Sectional Study by Ben Knudsen, Amr Madkour, Preetam Cholli, Alyson Haslam, Vinay Prasad

Get full text

Therapeutic anti-cancer vaccines: a systematic review of prospective intervention trials for common hematological malignanciesResearch in context by Darshi Shah, Veer Shah, Karan Shah, Prachi J. Shah, Muatassem Alsadhan, Alyson Haslam, Vinay Prasad, Muzaffar H. Qazilbash, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin

Get full text

Assessing patient risk, benefit, and outcomes in drug development: a decade of vemurafenib clinical trials by Taylor Gardner, Jacob Duncan, Griffin K. Hughes, Ryan McIntire, Brooke Gardner, Andriana Peña, Chase Ladd, Kelsey Snider, Ryan Ottwell, Jordan Tuia, Alyson Haslam, Vinay Prasad, Matt Vassar

Get full text

An evaluation of selinexor’s clinical trial portfolio: a cross-sectional study by Annes Elfar, Andrew V. Tran, Joseph Case, Cole Wayant, Griffin K. Hughes, Ryan McIntire, Brooke Gardner, Chase Ladd, Andriana M. Peña, Jordan Tuia, Alyson Haslam, Vinay Prasad, Matt Vassar

Get full text